Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs

Class:IdLiteratureReference:5657794
_displayNameIG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs
_timestamp2014-12-16 03:53:01
author[Person:5657758] Efimova, Elena V
[Person:5657745] Al-Zoubi, Adeeb M
[Person:5657762] Martinez, Osvaldo
[Person:5657767] Kaithamana, Shashi
[Person:5657802] Lu, Shenfeng
[Person:5657748] Arima, Takayasu
[Person:5657741] Prabhakar, Bellur S
created[InstanceEdit:5657736] Shamovsky, V, 2014-12-16
journalOncogene
pages1076-87
pubMedIdentifier14716293
titleIG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs
volume23
year2004
(literatureReference)[Reaction:5626953] TNF-α:TNFR1 binds DENN/MADD [Homo sapiens]
[Summation:5657769] MAPK activating death domain (MADD) and DENN-SV are known to...
[Change default viewing format]
No pathways have been reviewed or authored by IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs (5657794)